Latigo Biotherapeutics is a clinical-stage biotech focused on developing best-in-class non-opioid pain medicines that target pain at its source via selective Nav1.8 inhibition. Its lead candidate, LTG-001, is an oral selective Nav1.8 inhibitor for acute pain and reported positive Phase 1 first-in-human results, showing it was well tolerated with rapid absorption. A second oral Nav1.8 inhibitor, LTG-305, is in Phase 1 trials aimed at chronic pain and is being evaluated for safety, tolerability, and pharmacokinetics. The company’s stated goal is to provide effective, rapid-acting pain relief without the risk of addiction. Latigo recently closed a $150 million Series B to support advancement of its Nav1.8 clinical programs and the development of a broader pipeline. The company is based in Thousand Oaks, Calif. Latigo Biotherapeutics is a Thousand Oaks, CA-based clinical-stage biotech focused on non-opioid pain therapeutics that act on the fundamental mechanism of pain transduction. The company uses proprietary in-house technology that applies AI, machine learning, structure-based, and knowledge-based design to generate drugs against targets validated by human genetics. Its lead program, LTG-001, is an oral, selective Nav1.8 inhibitor currently in a Phase 1 clinical trial in healthy volunteers intended to treat acute and chronic pain. Latigo also maintains a suite of Nav1.8 inhibitors to address the broader clinical potential of the target and has additional small-molecule discovery programs against genetically identified targets. Leadership changes accompanying the financing include the appointment of Desmond Padhi as interim CEO and Nancy Stagliano as chair of the board. The company intends to use the proceeds to support continued advancement of its portfolio of novel pain therapeutics.

Total raised

$285M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2025